(Q38057962)

27 August 2017

title

Mammalian target of rapamycin as a rational therapeutic target for breast cancer treatment (English)

1 reference

27 August 2017

1 reference

Patricia Mucci LoRusso

series ordinal

1

1 reference

27 August 2017

publication date

30 October 2012

1 reference

27 August 2017

1 reference

27 August 2017

volume

84

1 reference

27 August 2017

issue

1

1 reference

27 August 2017

page(s)

43-56

1 reference

27 August 2017

cites work

Cancer statistics, 2010

1 reference

Breast cancer: understanding sensitivity and resistance to chemotherapy and targeted therapies to aid in personalised medicine.

21 January 2018

1 reference

Mammalian target of rapamycin: biological function and target for novel anticancer agents

21 January 2018

1 reference

Deciphering the role of PI3K/Akt/mTOR pathway in breast cancer biology and pathogenesis

21 January 2018

1 reference

Targeting endocrine resistance: is there a role for mTOR inhibition?

21 January 2018

1 reference

Structure of the human mTOR complex I and its implications for rapamycin inhibition.

21 January 2018

1 reference

New strategies in estrogen receptor-positive breast cancer

21 January 2018

1 reference

"Overcoming breast cancer drug resistance with mTOR inhibitors". Could it be a myth or a real possibility in the short-term future?

21 January 2018

1 reference

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

21 January 2018

1 reference

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer

21 January 2018

1 reference

Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients

21 January 2018

1 reference

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

21 January 2018

1 reference

Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer

21 January 2018

1 reference

Combination therapy for treating breast cancer using antiestrogen, ERA-923, and the mammalian target of rapamycin inhibitor, temsirolimus

21 January 2018

1 reference

Antiangiogenic potential of the Mammalian target of rapamycin inhibitor temsirolimus

21 January 2018

1 reference

Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer.

21 January 2018

1 reference

Phase II study of temsirolimus (CCI-779), a novel inhibitor of mTOR, in heavily pretreated patients with locally advanced or metastatic breast cancer

21 January 2018

1 reference

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells

21 January 2018

1 reference

Preclinical testing of clinically applicable strategies for overcoming trastuzumab resistance caused by PTEN deficiency.

21 January 2018

1 reference

Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling

21 January 2018

1 reference

Clinical pharmacokinetics of everolimus

21 January 2018

1 reference

Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants

21 January 2018

1 reference

Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163.

21 January 2018

1 reference

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

21 January 2018

1 reference

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab

21 January 2018

1 reference

Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy.

21 January 2018

1 reference

Comparison of the effects of the PI3K/mTOR inhibitors NVP-BEZ235 and GSK2126458 on tamoxifen-resistant breast cancer cells

21 January 2018

1 reference

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

Preclinical characterization of OSI-027, a potent and selective inhibitor of mTORC1 and mTORC2: distinct from rapamycin

21 January 2018

1 reference

The selective class I PI3K inhibitor CH5132799 targets human cancers harboring oncogenic PIK3CA mutations

21 January 2018

1 reference

Antitumor efficacy of PKI-587, a highly potent dual PI3K/mTOR kinase inhibitor

21 January 2018

1 reference

Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor

21 January 2018

1 reference

Ridaforolimus (AP23573; MK-8669), a potent mTOR inhibitor, has broad antitumor activity and can be optimally administered using intermittent dosing regimens

21 January 2018

1 reference

A phase I trial to determine the safety, tolerability, and maximum tolerated dose of deforolimus in patients with advanced malignancies

21 January 2018

1 reference

Effects of the dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 on the tumor vasculature: implications for clinical imaging

21 January 2018

1 reference

The PI3 kinase/mTOR blocker NVP-BEZ235 overrides resistance against irreversible ErbB inhibitors in breast cancer cells.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000343063

1 reference

27 August 2017

1 reference